The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $172.95

Today's change+0.29 +0.17%
Updated March 31 1:58 PM EDT. Delayed by at least 15 minutes.
 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $172.95

Today's change+0.29 +0.17%
Updated March 31 1:58 PM EDT. Delayed by at least 15 minutes.

Salix Pharmaceuticals Ltd Hits New 100-day High

Salix Pharmaceuticals Ltd is up today by (U.S.)$0.29 or 0.17% to (U.S.)$172.95 and setting a new 100-day high. Over the last five days, shares are unchanged, but have gained 50.47% over the last year to date. This security has outperformed the S&P 500 by 55.94% during the last year.

Key company metrics

  • Open(U.S.) $172.72
  • Previous close(U.S.) $172.65
  • High(U.S.) $172.95
  • Low(U.S.) $172.71
  • Bid / Ask(U.S.) $172.94 / (U.S.) $172.95
  • YTD % change+50.47%
  • Volume751,758
  • Average volume (10-day)1,633,084
  • Average volume (1-month)4,088,269
  • Average volume (3-month)3,345,604
  • 52-week range(U.S.) $86.00 to (U.S.) $172.98
  • Beta0.77
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward46.46×
  • Forward PEG2.85×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$6.51
Updated March 31 1:58 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-36.60%

Although this company's net profit margin is negative, it is above the industry average and implies that Salix Pharmaceuticals Ltd is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.22%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue13342376403
Total other revenue--------
Total revenue13342376403
Gross profit-17255271286
Total cost of revenue3086105117
Total operating expense437431333423
Selling / general / administrative137178138207
Research & development67372641
Depreciation / amortization54545454
Interest expense (income), net operating--------
Unusual expense (income)14977104
Other operating expenses, total--------
Operating income-423-8943-20
Interest income (expense), net non-operating-43-43-42-43
Gain (loss) on sale of assets--------
Other--------
Income before tax-467-1341-63
Income after tax-288-930-35
Income tax, total-180-410-28
Net income-288-930-35
Total adjustments to net income--------
Net income before extra. items-288-930-35
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-288-930-35
Inc. avail. to common incl. extra. items-288-930-35
Diluted net income-288-930-35
Dilution adjustment0--00
Diluted weighted average shares64647563
Diluted EPS excluding extraordinary itemsvalue per share-4.51-1.460.01-0.55
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-3.00-0.680.12-0.50